Snda
In Vitro in Vivo Correlation
Scale up and post approval changes(supac)
Presented By : Guided By : Ch.Mahesh Babu.Mrs.Mcthel M.PHARMACY Asst.professor Dept of pharmaceutics NIRMALA COLLEGE OF PHARMACY.
Dissolution
Bcs classification system
M7_Step_2
Diteba Corporate Capabilities
In-Vivo In-Vitro Correlation
IV Pan-American Conference BE PANDRH Working Group Salomon Stavchansky PhD Alcon Centennial Professor of Pharmaceutics The University of Texas at Austin.
1 Quality Risk Management Advisory Committee of the Office of Pharmaceutical Science Manufacturing Subcommittee July 20, 2004 Frederick Razzaghi ICH Q9.
ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.
